Skip to content


Zepzelca, Lurbinectedin (lurbinectedin) is a small molecule pharmaceutical. Lurbinectedin was first approved as Zepzelca on 2020-06-15. It is used to treat small cell lung carcinoma in the USA. Zepzelca's patent is valid until 2024-12-13 (FDA).
Trade Name Lurbinectedin
Common Name Lurbinectedin
Indication small cell lung carcinoma
Drug Class Ecteinascodin derivatives
Get full access now